Report of Foreign Issuer (6-k)

 

FORM 6-K

 

 

SECURITIES AND EXCHANGE COMMISSION 


Washington D.C. 20549

 

 

Report of Foreign Issuer

 

 

Pursuant to Rule 13a-16 or 15d-16 of 


the Securities Exchange Act of 1934

 

 

 

For period ending  1 December 2016

 

GlaxoSmithKline plc

(Name of registrant) 


 

 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices) 


 

 

 

Indicate by check mark whether the registrant files or

will file annual reports under cover Form 20-F or Form 40-F 


 

 

 

Form 20-F x     Form 40-F 


 

-- 


 

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the

information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934. 


 

 

 

Yes      No x

 

 

GlaxoSmithKline plc

 

Total Voting Rights and Capital

 

In conformity with Disclosure and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following:

 

The Company's issued share capital as at 30 November 2016 consisted of 5,367,734,859 ordinary shares of 25 pence each ('Ordinary Shares'), of which 491 ,505,950 Ordinary Shares were held in Treasury.

 

Therefore, the total number of voting rights in the Company is 4,876,228,909. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

 

V A Whyte

Company Secretary

 

1 December 2016

 

 

 

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised. 


 

	GlaxoSmithKline plc
	(Registrant)
Date: December 01, 2016
	By: VICTORIA WHYTE --------------------------
	Victoria Whyte
	Authorised Signatory for and on
	behalf of GlaxoSmithKline plc